Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | VSIR | Q9H7M9 | 7/20 | 0.40 |
| ▸ | TP53 | P04637 | 5/20 | 0.37 |
| ▸ | POLB | P06746 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10179942 | 0.97 | S1PR1 (0.45) | S1PR1VSIRTP53POLBNPC1 | |
| Formic Acid SCHEMBL3764768 | 0.91 | S1PR1 (0.48) | S1PR1TP53POLBNPC1RAB9A | |
| SCHEMBL10181644 | 0.89 | S1PR1 (0.47) | S1PR1VSIRTP53POLBNPC1 | |
| SCHEMBL3751202 | 0.89 | S1PR1 (0.44) | S1PR1TP53POLBNPC1RAB9A | |
| SCHEMBL3756265 | 0.88 | NPC1 (0.41) | S1PR1VSIRTP53POLBNPC1 | |
| SCHEMBL3762967 | 0.87 | S1PR1 (0.45) | S1PR1VSIRTP53POLBNPC1 | |
| SCHEMBL3757116 | 0.86 | S1PR1 (0.49) | S1PR1TP53POLBNPC1RAB9A | |
| SCHEMBL3456129 | 0.86 | S1PR1 (0.47) | S1PR1TP53POLBNPC1RAB9A | |
| SCHEMBL10179080 | 0.86 | S1PR1 (0.49) | S1PR1TP53POLBNPC1RAB9A | |
| Formic Acid SCHEMBL3756147 | 0.85 | S1PR1 (0.45) | S1PR1TP53POLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202856-B2 | Triazole oxadiazoles derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | OXA1L, RO60, PDCD11 | S1PR1 517/4885VSIR 1430/4885TP53 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.